Repros Therapeutics says positive results from Phase II trial of uterine fibroids drug; shares jump

pharmafile | April 15, 2016 | News story | Medical Communications, Research and Development Repros Therapeutics, Shares, US FDA, drug trial, uterine fibroids 

Shares in Repros Therapeutics (Nasdaq: RPRX) surged to close over 18% Thursday after the company announced positive mid-stage trial results for its drug candidate to treat uterine fibroids.

The company said the trial showed its Proellex significantly reduced excessive menstrual bleeding in women with uterine fibroids. The company will now work with the US Food and Drug Administration (FDA) to plan a Phase III trial.

Repros Therapeutics is engaged in the development of new drugs to treat hormonal and reproductive system disorders.

Shares in the company closed up 18.7% at $2.67 Thursday on the Nasadq.

Anjali Shukla

Related Content

Pfizer and Myovant’s menstrual blood loss treatment reports 78% effectiveness

Pfizer and Myovant Science’s relugolix treatment to reduce menstrual blood loss in women with uterine …


Lawsuit against FDA claims Bernie Sanders played role in approval of rival drug

Catalyst Pharmaceutical is attempting to show in court that pressure from US Senator Bernie Sanders …


Acasti’s shares plunge as new drug does not meet primary endpoint

Acasti Pharma’s shares plunged by as much as 67% this week as its drug CaPre …

Latest content